Development Agreements in the Health Care Technology Industry
16 Contracts & Agreements
- BIOTRICITY INC. (2 contracts)
- HTG MOLECULAR DIAGNOSTICS, INC (12)
- KELINDA (1)
- PARALLAX HEALTH SCIENCES, INC. (1)
- First Amendment to Amended and Restated IVD Test Development and Component Supply Agreement, dated April 23, 2019, by and between Illumina, Inc. and the Registrant (HTG MOLECULAR DIAGNOSTICS, INC, Filed With SEC on May 9, 2019)
- Fourth Amendment to Statement of Work No. 2, dated February 15, 2019, under Master Assay Development, Commercialization and Manufacturing Agreement between the Registrant and... (HTG MOLECULAR DIAGNOSTICS, INC, Filed With SEC on May 9, 2019)
- Excerpt from the requirements specification for KELINDA mobile application development (KELINDA, Filed With SEC on December 26, 2018)
- First Amendment to Statement of Work No. 3, dated September 21, 2018, under Master Assay Development, Commercialization and Manufacturing Agreement between the Registrant and... (HTG MOLECULAR DIAGNOSTICS, INC, Filed With SEC on November 8, 2018)
- Third Amendment to Statement of Work No. 2, dated September 27, 2018, under Master Assay Development, Commercialization and Manufacturing Agreement between the Registrant and... (HTG MOLECULAR DIAGNOSTICS, INC, Filed With SEC on November 8, 2018)
- Second Amendment to Statement of Work No. 2, dated August 13, 2018, under Master Assay Development, Commercialization and Manufacturing Agreement between the Registrant and QIAGEN... (HTG MOLECULAR DIAGNOSTICS, INC, Filed With SEC on November 8, 2018)
- First Amendment to Statement of Work No. 2, dated August 7, 2018, under Master Assay Development, Commercialization and Manufacturing Agreement between the Registrant and QIAGEN... (HTG MOLECULAR DIAGNOSTICS, INC, Filed With SEC on November 8, 2018)
- Statement of Work No. 3, dated January 12, 2018, under Master Assay Development, Commercialization and Manufacturing Agreement between the Registrant and QIAGEN Manchester Limited (HTG MOLECULAR DIAGNOSTICS, INC, Filed With SEC on May 10, 2018)
- Statement of Work No. 2, dated October 26, 2017, under Master Assay Development, Commercialization and Manufacturing Agreement between the Registrant and QIAGEN Manchester Limited (HTG MOLECULAR DIAGNOSTICS, INC, Filed With SEC on March 23, 2018)
- Amendment to Statement of Work No. 1, dated December 18, 2017, under Master Assay Development, Commercialization and Manufacturing Agreement between the Registrant and QIAGEN... (HTG MOLECULAR DIAGNOSTICS, INC, Filed With SEC on March 23, 2018)
- First Amendment to Master Assay Development, Commercialization and Manufacturing Agreement (HTG MOLECULAR DIAGNOSTICS, INC, Filed With SEC on August 8, 2017)
- AMENDED AND RESTATED IVD TEST development AND COMPONENT SUPPLY AGREEMENT (HTG MOLECULAR DIAGNOSTICS, INC, Filed With SEC on August 8, 2017)
- Master Assay Development, Commercialization and Manufacturing Agreement (HTG MOLECULAR DIAGNOSTICS, INC, Filed With SEC on March 23, 2017)
- SOFTWARE DEVELOPMENT AND SERVICES AGREEMENT (BIOTRICITY INC., Filed With SEC on December 13, 2016)
- SOFTWARE DEVELOPMENT AND SERVICES AGREEMENT (BIOTRICITY INC., Filed With SEC on September 30, 2016)
- Development and Supply Agreement between Parallax Diagnostics, Inc. and Corder Engineering, LLC dated July 1, 2011 (PARALLAX HEALTH SCIENCES, INC., Filed With SEC on November 15, 2012)
